chartexchange

NGNE
Neurogene, Inc. Common Stock
stockNASDAQ

At CloseNov 18, 2026 3:59:50 PM EST
23.17USD+0.281%(+0.07)248,971
After-hoursNov 18, 2026 4:26:30 PM EST
23.14USD-0.108%(-0.03)
Loading…
Loading…
478.40M
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Previous Close
$23.10
Beta
1.45
52-Week High
$43.66 2026-07-09
52-Week Low
$15.93 2026-02-05
SMA 50
$27.31
SMA 200
$28.25
Avg. Vol 10D
289,504
Avg. Vol 30D
337,906
Avg. Vol 90D
274,150
Relative Vol
0.74
12.54M
0.3300%
NGNE Profile

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.

NGNE Performance
PeriodPriceDateChangeBeta
1W23.902026-11-12-3.31%1.750
1M24.172026-10-19-4.39%2.147
3M39.432026-08-19-41.39%1.423
6M26.882026-05-19-14.03%1.080
1Y20.992025-11-19+10.10%1.451
2Y17.232024-11-19+34.13%—
NGNE Stock Summary

Neurogene, Inc. Common Stock (NASDAQ:NGNE) stock price today is $23.11, and today's volume is 248,971. NGNE is up 0.043% today. The 30 day average volume is 337,906. NGNE market cap is $478.40M with 20.70M shares outstanding.